Combination therapy of first and third generation EGFR-TKIs for an advanced lung adenocarcinoma patient harboring EGFR mutations and amplification: a case report

The paradigm for the pharmacological management of advanced non-small cell lung cancer (NSCLC) has been revolutionized by the development of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs). Developing resistance to target therapy is unavoidable. Mostly, treatments for singl...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yongxing, Meng, Chong, Liu, Kai, Liu, Lirong, Mo, Rubing, Chen, Shuyin, Xie, Shuying, Xiang, Jianxing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798383/
https://www.ncbi.nlm.nih.gov/pubmed/35117738
http://dx.doi.org/10.21037/tcr.2020.04.06

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8798383/
https://www.ncbi.nlm.nih.gov/pubmed/35117738
http://dx.doi.org/10.21037/tcr.2020.04.06

Ejemplares similares